SELENITE is not **SELENIUM**

Dr. X Forceville MD PhD, Intensivist, Anesthesiologist, Nutritionist Former ICU Head

CIC INSERM 1414, CHU de Rennes

Selenite (Na₂SeO₃) ethical concerns

Conflicts of interest

- Main Shareholder of a very small start up SERENITE-Forceville
 Patent filed in 2015 on a treatment of sepsis combining antioxidant and oxidant selenocompounds
- Working on that field for 30 years

For details

2 recent bound review and forum review articles in ARS (Antioxidant and Redox Signaling is a leading journal in oxidation field):

- Selenocompounds and Sepsis, Redox Bypass Hypothesis:
 Part A: Early acute phase of sepsis an extraordinary redox situation
 (Leukocyte/Endothelium Interaction Leading to Endothelial Damage)
 X Forceville, P Van Antwerpen, JC Preiser,
 Antioxid Redox Signal. 2021;35(2):113-38.
- Selenocompounds and Sepsis, Redox Bypass Hypothesis: Part B: Selenocompounds in the Management of Early Sepsis X Forceville, P Van Antwerpen, D Annane, JL Vincent Antioxid Redox Signal., 2022 37(13-15):998-1029

Free of access via pubmed (in beta version via HAL)

•

Selenite Janus Molecule Dual Action (Quantum Chemistry)

1- Selenite is a poison as toxic as arsenic LD ≠ weight of

- Oxidant molecule (orally Lethal Dose min. LD ≠ 3-5 mg Se/kg)
- Toxicity is most probably increase in sepsis (i.e. min. LD 0.3-0.6 mg Server)
- But toxicity is most probably more concentration than dose dependent. Weight of 3 caffe beans
- Multiple organ failure (cardiorespiratory distress at foreground)


2- Selenite is a chemotherapeutic agent (stop in G2M phase):

- Toxicity of selenite is dose but even more concentration dependent. Selenite is cytotoxic for concentration > 1-5 μmole Se/L. Selenite is actively incorporate on active cells and damage many targets in cells :
 - DNA (double strand break),
 - Mitochondria,
 - Endoplasmic reticulum,
 - Proteins (disulfur bridge S-S)

3- Selenite could deliver Se after a complex metabolism (pro-antioxidant)

- Physiologically in the liver (3-4 mg Se content)
- Se is essential for vital antioxidant selenoenzymes
- Total body content (TBSe) 10-15 mg Se
- Orally Upper Limit 400 μg Se/d (or 200 μgSe /d), Low Adverse Effect Level 900 μg Se/d


Selenite Cytotoxicity (in vitro, in animal, in Phase I)



See part B (A) review articles - ARS X Forceville, 2022 Fig 2, Table 1, (Brodin O, 2015; Breuer, O 2023)

Teratogenic, mutagenic, most probably carcinogenic (its metabolite HSe- is carcinogenic)

2a - General Acute Toxicity Mimic Septic Shock



4b - Plasma Se and Selenoenzymes (which are decreased in sepsis: 0.3 mg Se - 2% of TBSe)

- Selenocysteine (Sec)
 - Selenoprotein-P (SELENOP) ≈ 60%
 - Specific and non-Specific binding (low pH)
 - Double function: Sec Transport and antioxidant enzyme (TXRND)
 - Protection of endothelium against peroxynitrite (ONOO⁻);
 Endothelium Surface Layer ESL
 - Glutathion peroxidase 3 (GPX 3) ≈ 30%
 - Very low glutathione concentration in plasma
 - Could have a protective effect for basal membrane
- Selenomethionine (SeMet)
 - Albumin ≈ 10%

See part B article for the blockage of SELENOP synthesis in sepsis, and the article of Wang, Forceville, 2010 Shock for selenite action as selenium provider or drug action.

Dose Expression Problem of Selenite Administration

Molecular weight

- $Na_2 \neq 23 \text{ g x} 2 \text{Se} \neq 79 \text{ g} O_3 16 \text{ g x} 3$
- Se = $0.46 \text{ Na}_2\text{SeO}_3$

Correspondence

• 1 mg Selenite ≠ 0.5 mg Se as selenite

Mistake

- Mistake in expression of delivered amout could lead to a wrong message lowering the administrated dose by a factor 2
- (e.g. indicating 2 mg selenite for a real administration of 2 mg
 Se as selenite).

Main Ethical Concerns for Selenite

- Selenite should be recognized as drug in cytotoxic range
 - Above a nutritional dose and especially if reaching cytotoxic concentration (intravenous, and especially if bolus injection reaching concentration > 1-5 µmol Se/L) selenite should be considered as an active ingredient (i.e. drug)
- When acting as drug it should follow rules of drug development and classified as Active Ingredient (AI) (e.g. drug) by Medicines Agency.
- Direct experimentation of selenite in patients in drug range raise ethical concerns and even more in patients with low mortality rate.
 - Especially as selenite is teratogenic, mutagenic and most probly carcinogenic and there is no pharmacovigilance;
 - Not avoiding acute toxicity, which seems increased in sepsis and difficult to spit from sepsis (or acute inflammation) evolution.